Single-Photon Emission Computed Tomography (SPECT) Market Size & Growth Forecast 2027–2036, By Segments (Application Channel, End Use Channel, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Single-Photon Emission Computed Tomography Market size was valued at USD 4.04 billion in 2026 and is anticipated to grow at a 2.64% CAGR from 2027 to 2036, crossing USD 5.24 billion by 2036. The industry revenue for 2027 is calculated at USD 4.13 billion.
Get more details on this report
Request Free Sample ReportSingle-Photon Emission Computed Tomography (SPECT) Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 46.56% share due to strong nuclear imaging infrastructure, widespread clinical use in cardiology and oncology, and established hospital-based diagnostic workflows.
- Asia Pacific is growing at 3.31% CAGR as healthcare systems expand imaging access, invest in diagnostic capacity, and gradually integrate advanced nuclear medicine technologies into clinical practice.
Segment Momentum
- Oncology accounted for 49.98% of the market in 2026 and remains the fastest-growing application because SPECT is widely used to assess cancer progression, treatment response, and ongoing patient management.
- Diagnostics imaging centers are expanding fastest as providers and patients increasingly value dedicated outpatient imaging services that offer streamlined scheduling, efficient workflows, and improved access for routine SPECT procedures.
Market Expansion Drivers
- Rising global cancer burden increasing demand for advanced nuclear diagnostic imaging systems.
- Growing adoption of hybrid SPECT/CT systems improving diagnostic precision and clinical efficiency.
- Expanding radiopharmaceutical research strengthening development of specialized molecular imaging applications.
Leading Market Participants
- Prominent players in the single-photon emission computed tomography market include GE HealthCare Technologies Inc. (United States), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Spectrum Dynamics Medical Ltd. (Israel), Mediso Medical Imaging Systems Ltd. (Hungary), MiE GmbH (Germany), Canon Medical Systems Corporation (Japan), Shimadzu Corporation (Japan), TTG Imaging Solutions, LLC (Digirad Corporation) (United States), Rigaku Corporation (MILabs B.V.) (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.04 billion
- 2027 Estimated Market Size: USD 4.13 billion.
- Projected Market Size: USD 5.24 billion by 2036
- Growth Forecast: 2.64% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Oncology (Application Channel) | Hospitals (End Use Channel) | Hybrid SPECT Systems (Product)
- Emerging Opportunity Segment: Oncology (Application Channel) | Diagnostics Imaging Centers (End Use Channel) | Hybrid SPECT Systems (Product)
Market Growth Drivers and Industry Trends
Rising global cancer burden increasing demand for advanced nuclear diagnostic imaging systems
The growing incidence of cancer is creating greater demand for advanced diagnostic modalities, and the single-photon emission computed tomography market is benefiting from the need for accurate disease detection, staging, and treatment assessment. SPECT enables clinicians to evaluate functional and physiological changes that may not be fully captured through conventional anatomical imaging, supporting applications in oncology alongside broader diagnostic workflows. As healthcare systems strengthen cancer screening and diagnostic capacity, nuclear imaging technologies are increasingly incorporated into clinical pathways where functional information can assist physicians in identifying abnormalities and evaluating disease progression.
Growing adoption of hybrid SPECT/CT systems improving diagnostic precision and clinical efficiency
Integration of functional SPECT imaging with anatomical computed tomography is enhancing the clinical utility of nuclear imaging, positioning the single-photon emission computed tomography market for broader adoption across diagnostic settings. Hybrid SPECT/CT systems allow clinicians to correlate radiotracer distribution with detailed anatomical information, helping improve lesion localization and interpretation while reducing uncertainty during diagnosis. Their ability to consolidate complementary imaging information within a single workflow can also support more efficient clinical decision-making, particularly in oncology and other specialties requiring precise assessment of disease location and activity.
Expanding radiopharmaceutical research strengthening development of specialized molecular imaging applications
Advances in radiopharmaceutical research are broadening the range of molecular targets and clinical applications accessible through nuclear imaging, creating new opportunities for the single-photon emission computed tomography market. Research into targeted radiotracers can enable imaging of specific biological processes and disease characteristics, supporting more specialized diagnostic approaches beyond conventional anatomical assessment. As radiopharmaceutical development progresses, greater availability of application-specific tracers can encourage healthcare providers to use SPECT-based imaging for targeted evaluation, treatment planning, and monitoring across emerging molecular imaging applications.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer burden increasing demand for advanced nuclear diagnostic imaging systems | 1.80% | Moderate | North America, Europe, Asia Pacific | High | Mid Term |
| Growing adoption of hybrid SPECT/CT systems improving diagnostic precision and clinical efficiency | 1.50% | High | North America, Europe | Medium | Mid Term |
| Expanding radiopharmaceutical research strengthening development of specialized molecular imaging applications | 1.20% | High | North America, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the single-photon emission computed tomography market, accounting for 46.56% share in 2026, supported by advanced diagnostic infrastructure, broad adoption of nuclear medicine technologies, and strong demand for sophisticated imaging in cardiovascular, neurological, and oncology applications. The region benefits from established healthcare systems with substantial investment in diagnostic equipment and specialized imaging facilities, while favorable reimbursement structures and growing emphasis on early disease detection encourage the use of SPECT procedures. Continued integration of advanced image-processing capabilities and improvements in clinical workflow are also strengthening the role of SPECT within complex diagnostic pathways.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing region, driven by expanding healthcare infrastructure, increasing access to advanced diagnostic imaging, and rising demand for earlier and more accurate disease detection. Growing healthcare expenditure and the modernization of hospitals and diagnostic centers are creating broader opportunities for nuclear imaging technologies across emerging healthcare markets. In addition, increasing awareness of cardiovascular and neurological disorders, expansion of specialized medical facilities, and efforts to improve diagnostic capacity are supporting wider adoption of SPECT systems. The region's developing healthcare ecosystem and ongoing investments in medical technology are expected to sustain strong momentum for market expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Diagnostic ImagingGermany emphasizes single-photon emission computed tomography systems that deliver consistent diagnostic performance across specialized medical centers. Investment focuses on advanced imaging capabilities, optimized workflows, and integration with comprehensive nuclear medicine services.
France 🇫🇷
Hospital Imaging OptimizationFrance focuses on optimizing single-photon emission computed tomography services through equipment modernization and standardized diagnostic pathways. Healthcare institutions value systems that improve image consistency while supporting multidisciplinary patient care.
Italy 🇮🇹
Specialized Nuclear MedicineItaly supports the single-photon emission computed tomography market through specialized nuclear medicine departments serving diverse diagnostic needs. Clinical priorities include dependable imaging performance, efficient patient throughput, and compatibility with evolving diagnostic protocols.
Japan 🇯🇵
Clinical Imaging EfficiencyJapan advances the use of single-photon emission computed tomography through healthcare facilities seeking reliable diagnostic imaging with streamlined clinical workflows. The market favors compact, high-performance systems that support routine evaluation of complex medical conditions.
South Korea 🇰🇷
Digital Imaging AdvancementSouth Korea strengthens its single-photon emission computed tomography market by integrating digital imaging technologies into modern hospital environments. Healthcare providers prioritize enhanced image quality, faster examinations, and efficient management of diagnostic procedures.
United States 🇺🇸
Advanced Nuclear ImagingThe U.S. single-photon emission computed tomography market supports growing demand for functional imaging in cardiology, neurology, and oncology. Healthcare providers prioritize imaging systems with improved diagnostic accuracy, workflow efficiency, and compatibility with hybrid imaging technologies.
Segment Leadership and Growth Trends
Single-Photon Emission Computed Tomography (SPECT) Market Share (%), by Application Channel, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Channel Segment Analysis: Oncology (Largest & Fastest-Growing Segment)
The oncology segment was both the largest and fastest-growing application channel in the single-photon emission computed tomography (SPECT) market, accounting for a 49.98% share in 2026. SPECT plays an important role in nuclear medicine imaging by providing functional information that can complement anatomical imaging, supporting the assessment and management of cancer-related conditions. Growing emphasis on earlier detection, treatment planning, and monitoring of disease progression is increasing demand for advanced diagnostic imaging approaches. The expanding role of molecular and functional imaging in oncology is further reinforcing this segment's leading position and growth potential.
End Use Channel Segment Analysis: Hospitals (Largest Segment) vs Diagnostics Imaging Centers (Fastest-Growing Segment)
Hospitals held the largest share of the single-photon emission computed tomography (SPECT) market with 49.79% in 2026, owing to their comprehensive diagnostic capabilities and ability to integrate nuclear medicine imaging with broader clinical services. Hospitals typically provide access to specialized imaging equipment, trained personnel, multidisciplinary care teams, and follow-up treatment services, making them important centers for SPECT-based examinations. The continued need for advanced diagnostic imaging within complex patient-care pathways is supporting strong hospital-based utilization.
Diagnostics imaging centers are the fastest-growing end-use category, supported by increasing demand for specialized and accessible diagnostic services outside traditional hospital settings. Dedicated imaging centers can provide focused diagnostic capabilities and convenient access to imaging procedures, helping address growing demand for efficient medical imaging. Increasing specialization of diagnostic services and efforts to expand access to advanced imaging technologies are contributing to the segment's rapid growth.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application Channel | Cardiology, Oncology, Neurology, Others | Oncology | Oncology |
| End Use Channel | Hospitals, Diagnostics Imaging Centers, Research & Development Institutes, Others | Hospitals | Diagnostics Imaging Centers |
| Product | Stand-alone SPECT Systems, Hybrid SPECT Systems | Hybrid SPECT Systems | Hybrid SPECT Systems |
Competitive Landscape and Market Positioning
Leading companies in the single-photon emission computed tomography (SPECT) market:
1. GE HealthCare Technologies Inc. (United States)
2. Siemens Healthineers AG (Germany)
3. Koninklijke Philips N.V. (Netherlands)
4. Spectrum Dynamics Medical Ltd. (Israel)
5. Mediso Medical Imaging Systems Ltd. (Hungary)
6. MiE GmbH (Germany)
7. Canon Medical Systems Corporation (Japan)
8. Shimadzu Corporation (Japan)
9. TTG Imaging Solutions LLC (Digirad Corporation) (United States)
10. Rigaku Corporation (MILabs B.V.) (Japan)
The SPECT market is advancing through improved imaging technologies that enhance diagnostic accuracy and clinical efficiency. Continuous R&D is strengthening imaging resolution and reliability. New system innovations are supporting better clinical outcomes, while collaborative initiatives are improving integration with advanced medical imaging ecosystems.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (United States) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Koninklijke Philips N.V. (Netherlands) | |||||||
| Spectrum Dynamics Medical Ltd. (Israel) | |||||||
| Mediso Medical Imaging Systems Ltd. (Hungary) | |||||||
| MiE GmbH (Germany) | |||||||
| Canon Medical Systems Corporation (Japan) | |||||||
| Shimadzu Corporation (Japan) | |||||||
| TTG Imaging Solutions LLC (Digirad Corporation) (United States) | |||||||
| Rigaku Corporation (MILabs B.V.) (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| GE HealthCare | Jun-26 | GE HealthCare introduced a suite of AI-enabled imaging software, radiopharmaceuticals, and nuclear medicine hardware solutions. These technologies optimize clinician workflows and advance the scalability of theranostics, supporting broader medical infrastructure adoption of high-performance SPECT imaging applications. |
| GE HealthCare | Apr-25 | GE HealthCare finalized the acquisition of the remaining stake in Nihon Medi-Physics, a developer of radiopharmaceuticals utilized in SPECT and PET imaging. This strategic transaction directly strengthens GE HealthCare’s molecular diagnostics portfolio and broadens its vertical capabilities in regional nuclear medicine imaging markets. |
| The Shrewsbury and Telford NHS Hospital Trust | Aug-24 | The Shrewsbury and Telford NHS Hospital Trust commissioned a new £3.6 million dual-head gamma camera system. This public healthcare capital deployment expands regional clinical capacity and enhances local diagnostic throughput for patients requiring critical SPECT-based molecular imaging procedures. |
| Cancer Centre London | May-24 | Cancer Centre London deployed a state-of-the-art SPECT/CT imaging system supplied by ICON and Nuffield Health. The integration of this dual-modality hybrid hardware materially upgrades the facility's local diagnostic capacity and clinical accuracy for oncology treatment planning. |
| GE HealthCare | Jan-24 | GE HealthCare announced an agreement to acquire MIM Software, a provider of medical imaging analysis and artificial intelligence solutions. The acquisition integrates advanced AI software into radiation oncology, diagnostic imaging, and molecular radiotherapy workflows, enhancing GE HealthCare’s technology footprint across distributed healthcare imaging networks. |
| Siemens Healthineers | Jun-22 | Siemens Healthineers launched Symbia Pro.Specta, a high-performance SPECT/CT imaging system that secured concurrent CE mark and FDA clearance. The commercialization of this platform, which features a low-dose 64-slice CT scanner, introduces advanced high-resolution multi-slice diagnostic capabilities to the market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Single-Photon Emission Computed Tomography (SPECT) Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Radiopharmaceutical Type | Technetium-99m, Iodine-123, Indium-111, Other Radiopharmaceuticals |
| Detector Technology | Anger Camera, Cadmium Zinc Telluride (CZT), Other Solid-State Detectors |
| Procurement Model | Direct Purchase, Distributor-Mediated Purchase, Leasing & Financing |
Single-Photon Emission Computed Tomography (SPECT) Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| SPECT Installed Base Modernization Outlook |
|
| Hybrid SPECT/CT Adoption Opportunity Assessment |
|
| Healthcare Provider Procurement and Capital Investment Benchmarking |
|
Need a different cut of the data?
Request Custom ResearchHow big is the single-photon emission computed tomography market?
What is the expected industry size of single-photon emission computed tomography by 2036?
How is oncology demand influencing investment in SPECT imaging systems?
Why are hybrid SPECT/CT systems gaining importance in diagnostic imaging modernization?
Why is oncology the leading application in the single-photon emission computed tomography (SPECT) market?
Why are diagnostics imaging centers the fastest-growing end-use segment in the single-photon emission computed tomography (SPECT) market?
Why is North America the largest SPECT market?
How is Asia Pacific contributing to growth in the SPECT market?
Who are the major participants shaping the single-photon emission computed tomography landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization